KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Other Operating Expenses: 2011-2024

Historic Other Operating Expenses for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to $72.9 million.

  • Travere Therapeutics' Other Operating Expenses fell 2.52% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 86.21%. This contributed to the annual value of $72.9 million for FY2024, which is 537.11% up from last year.
  • Per Travere Therapeutics' latest filing, its Other Operating Expenses stood at $72.9 million for FY2024, which was up 537.11% from $11.4 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Other Operating Expenses registered a high of $106.9 million during FY2020, and its lowest value of $3.8 million during FY2021.
  • Its 3-year average for Other Operating Expenses is $29.6 million, with a median of $11.4 million in 2023.
  • As far as peak fluctuations go, Travere Therapeutics' Other Operating Expenses tumbled by 96.43% in 2021, and later skyrocketed by 537.11% in 2024.
  • Over the past 5 years, Travere Therapeutics' Other Operating Expenses (Yearly) stood at $106.9 million in 2020, then tumbled by 96.43% to $3.8 million in 2021, then rose by 15.77% to $4.4 million in 2022, then spiked by 159.05% to $11.4 million in 2023, then skyrocketed by 537.11% to $72.9 million in 2024.